84 related articles for article (PubMed ID: 27866092)
1. Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy.
Li J; Jiang Y; Liu Y; Shao Z
Breast; 2017 Feb; 31():173-180. PubMed ID: 27866092
[TBL] [Abstract][Full Text] [Related]
2. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods.
Li J; Liu Y; Jiang Y; Shao Z
PLoS One; 2016; 11(6):e0157322. PubMed ID: 27299729
[TBL] [Abstract][Full Text] [Related]
4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
5. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
6. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
7. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
8. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
10. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
11. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
12. Older Patients With Early-stage Breast Cancer: Adjuvant Radiation Therapy and Predictive Factors for Cancer-related Death.
Nagar H; Yan W; Christos P; Chao KSC; Nori D; Ravi A
Am J Clin Oncol; 2017 Jun; 40(3):300-305. PubMed ID: 25333731
[TBL] [Abstract][Full Text] [Related]
13. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer.
Shen X; Anne PR; Keith SW; Wojcieszynski A; Mishra MV; Bar-Ad V; Showalter TN
Am J Clin Oncol; 2014 Jun; 37(3):241-7. PubMed ID: 23241502
[TBL] [Abstract][Full Text] [Related]
15. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
Leone J; Hassett MJ; Freedman RA; Tolaney SM; Graham N; Tayob N; Vallejo CT; Winer EP; Lin NU; Leone JP
JAMA Oncol; 2024 Apr; 10(4):508-515. PubMed ID: 38421673
[TBL] [Abstract][Full Text] [Related]
16. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ejlertsen B; Jensen MB; Mouridsen HT;
Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
[TBL] [Abstract][Full Text] [Related]
17. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.
Cossetti RJ; Tyldesley SK; Speers CH; Zheng Y; Gelmon KA
J Clin Oncol; 2015 Jan; 33(1):65-73. PubMed ID: 25422485
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.
Jatoi I; Chen BE; Anderson WF; Rosenberg PS
J Clin Oncol; 2007 May; 25(13):1683-90. PubMed ID: 17404367
[TBL] [Abstract][Full Text] [Related]
19. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
Anderson WF; Chen BE; Jatoi I; Rosenberg PS
Breast Cancer Res Treat; 2006 Nov; 100(1):121-6. PubMed ID: 16685588
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
